AstraZeneca has hit what appears to be a minor speed bump in gaining clearance in the U.S. for its subcutaneous (SC) version of lupus treatment Saphnelo. The FDA has sent the British drugmaker a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results